An Experimental Overview of a New Vasoactive Drug: Buflomedil HC1

Dubourg, Alain; Scamuffa, Robin F.
October 1981
Angiology;Oct1981, Vol. 32 Issue 10, p663
Academic Journal
A brief review of the pharmacology, pharmacokinetics, and metabolism of buflomedil-HCl is presented providing a pharmacologic basis for buflomedil therapy of ischemia associated with peripheral vascular disease. Buflomedil is readily absorbed in the gastrointestinal tract and has a plasma half-life of approximately 2-3 hours. The para-desmethyl derivative of buflomedil has been identified as a urinary metabolite. Pharmacologically, buflomedil increases perfusion to impaired vascular beds of the microcirculation, increases arterial perfusion with minimal effects on central hemodynamics, exhibits apparent oxygen "sparing" effects in animal experiments, demonstrates inhibitory effects on platelet aggregation, and, in preliminary experiments, appears to improve deformability of erythrocytes with abnormal fluidity. A nonspecific a-receptor blocking activity appears to be involved, at least in part, in these pharmacologic effects. The relative importance of these mechanisms/effects in the treatment of symptoms of vascular disease is unknown.


Related Articles

  • Using pharmacokinetic/pharmacodynamic priciples to optimize carbapenem use.  // Formulary;Jul2007 Supplement, Vol. 42, p11 

    The article presents the standards set to test the most effective and potent regimens in the U.S. The main pharmacokinetic (PK)/PD parameters are the ratio of the peak drug concentration to the minimum inhibitory concentration (TMIC) and the duration of time that drug concentrations remain above...

  • Clinical Pharmacokinetics and Metabolism of Bevantolol. Latts, Jeffrey R. // Angiology;Mar1986 Part 2, Vol. 37 Issue 3, p221 

    Bevantolol (the hydrochloride salt) has pharmacokinetic properties that are clinically advantageous. Bevantolol is well absorbed orally (> 70%); and the systemic bioavailability is 60%. Peak plasma concentrations are achieved 1 to 2 hours following an oral dose. Elimination is first-order with...

  • Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Suri, A.; Reddy, S.; Gonzales, C.; Knadler, M.P.; Branch, R.A.; Skinner, M.H. // International Journal of Clinical Pharmacology & Therapeutics;2005, Vol. 43 Issue 2, p78 

    Objective: To compare the pharmacokinetics of single-dose duloxetine in cirrhotic and healthy subjects. Methods: An open-label inpatient study com pared duloxetine pharmacokinetics in six subjects with moderate liver cirrhosis (Child-Pugh class B) to those in six healthy subjects. Subjects...

  • The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Oda, Manami; Kotegawa, Tsutomu; Tsutsumi, Kimiko; Ohtani, Yasukiyo; Kuwatani, Keiji; Nakano, Shigeyuki // European Journal of Clinical Pharmacology;Nov2003, Vol. 59 Issue 8/9, p615 

    Rationale and objective. Bromazepam, an anti-anxiety agent, has been reported to be metabolized by cytochrome P450 (CYP). However, the enzyme responsible for the metabolism of bromazepam has yet to be determined. The purpose of this study was to examine whether the inhibition of CYP3A4 produced...

  • Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Khayat, David; Rixe, Olivier; Brunet, René; Goupil, Alain; Bugat, Roland; Harousseau, Jean-Luc; Ifrah, Norbert; Puozzo, Christian // Cancer Chemotherapy & Pharmacology;Sep2004, Vol. 54 Issue 3, p193 

    As pharmacokinetics represents a bridge between pharmacological concentrations and clinical regimens, the pharmacokinetic exploration of the therapeutic dose range is a major outcome. This study was aimed at assessing pharmacokinetic linearity of i.v. vinorelbine through an open design with...

  • Biowaivers for Oral Immediate-Release Products: Implications of Linear Pharmacokinetics. Faassen, Fried; Vromans, Herman // Clinical Pharmacokinetics;2004, Vol. 43 Issue 15, p1117 

    Bioequivalence of drug formulations plays an important role in drug development. Recently, the Biopharmaceutical Classification System (BCS) has been implemented for the purpose of waiving bioequivalence studies on the basis of the solubility and gastrointestinal permeability of drug substance....

  • Reaction Phenotyping in Drug Discovery: Moving Forward with Confidence? Williams, J. Andrew; Hurst, Susan I.; Bauman, Jonathan; Jones, Barry C.; Hyland, Ruth; Gibbs, John P.; Obach, R. Scott; Ball, Simon E. // Current Drug Metabolism;Dec2003, Vol. 4 Issue 6, p527 

    For the pharmaceutical industry, one of the challenges in evaluating the risk of future compound attrition at the discovery stage is the successful prediction of the major routes of clearance in humans. For compounds cleared by metabolism, such information will help to avoid the development of...

  • Pooled Population Pharmacokinetic Analysis of Phase I, II and III Studies of Linifanib in Cancer Patients. Salem, Ahmed; Koenig, Denise; Carlson, Dawn // Clinical Pharmacokinetics;Apr2014, Vol. 53 Issue 4, p347 

    Background and Objective: Linifanib is a multi-targeted receptor tyrosine kinase inhibitor, which can inhibit members of the vascular endothelial growth factor and platelet-derived growth factor receptor families. The objective of this analysis was to characterize the population pharmacokinetics...

  • Poor Metabolizer.  // Encyclopedic Reference of Molecular Pharmacology;2004, p748 

    An encyclopedia entry for poor metabolizer is presented. It explains that it is a historically used pharmacogenetic term for a person with deficient metabolism with respect to substrates of a specified enzyme. Genetically, poor metabolizer is an autosomal recessively inherited drug metabolism...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics